Last reviewed · How we verify

NCT06946511

Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia

Not yet recruiting Phase 1, PHASE2 Last updated 1 May 2025
What this trial tests

Phase 1, PHASE2 trial testing Peptide PMS-001 Intravenous Injection in Dementia in 50 participants. Not yet recruiting.

Timeline
1 August 2025
Primary endpoint
31 January 2026
31 January 2026

Quick facts

Lead sponsorRuijin Hospital
PhasePhase 1, PHASE2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment50
Start date1 August 2025
Primary completion31 January 2026
Estimated completion31 January 2026
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Ruijin Hospital

Who can join

Adults 60 to 80, any sex, with Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, randomized, double-blind, placebo-controlled study. Patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and 75mg) or the placebo control group. After learning and training, participants will receive an injection of PMS-001. The efficacy and safety of the intervention will be assessed at 1 hour, 1 day, 3 days, and 1 week post-intervention. This study aims to evaluate the effects of PMS-001 on improving long-delay recall in patients with moderate to severe dementia, as well as its safety profile.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dementia

Currently open trials in the same condition.

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06946511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing